Canaccord analyst Edward Nash lowered the firm’s price target on Corcept Therapeutics to $32 from $33 and keeps a Buy rating on the shares. The analyst said the company remains on track to report top-line data from the Phase III GRACE trial for relacorilant in Cushing’s in 2023, followed by an NDA submission in 1Q24. The target change is primarily related to an adjustment in projected relacorilant and Korlym sales revenue in 2024, our estimated launch year for relacorilant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics commences tender offer to purchase 7.5M shares
- Corcept Therapeutics sees FY23 revenue $430M- $450M, consensus $434.79M
- Corcept Therapeutics reports Q4 EPS 14c, consensus 22c
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
- Corcept downgraded to Hold at Jefferies ahead of 2023 guidance